CDKN3 and colonic neoplasm: As the functional mechanism of wild-type p53 expression is known to be mediated by the activation of its primary effector target p21 – a cyclin-dependent kinase inhibitor (CDKi) (26), we sought to determine the p21 expression in colon cancer cells in response to OX treatment in the context of p53 status.